Prospective on evaluation of use of , â??AyurCoro3â?? as an add on medication for the treatment purpose in COVID-19 patients

Prospective , multi center ,single blind , randomized controlled study on evaluation of use of , â??AyurCoro3â?? as an adjuvant for the treatment purpose in mild to moderate COVID-19 patients at tertiary care center. - AyurCoro3

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028333

Enrollment

500

Registered

2020-10-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: AyurCov3: 10 Ml three times a day for 3 days . One day medication Control Intervention1: Standard of care: As per routine clinical care

Eligibility

Inclusion criteria

Inclusion criteria: 1. Laboratory confirmed diagnosis of Mild to Moderate COVID-19 patients 2. Agree to consent for the study. 3. All Age groups above 18 Years 4. All genders.

Exclusion criteria

Exclusion criteria: 1. Patients on ventilator 2. Critically ill patient 3. Dyspnea, respiratory frequency >= 30/min, 4. Blood oxygen saturation (SpO2) 5. PaO2/FiO2 ratio 50% within 24 to 48 hours 6. Patients with altered mental state 7. Patients with multiple organ failure requiring ICU monitoring and treatment. 8. Patients with respiratory failure and requiring mechanical ventilation/ 9. Patient who have participated in another investigational study within 3 months prior to enrollment in this study 10. Investigators, study personnel and their first-degree relatives. 11. Pregnant Patients 12. Current or future involvement in the active treatment phase of other interventional research studies (excluding observational/non-interventional studies). 13. Any other clinical reason which may preclude entry in the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
Time (Days) to clinical improvement from study enrolmentTimepoint: At Baseline, Day three , Day five and Day seven	—

Secondary

Measure	Time frame
1. Clinical status as assessed by the 9-point ordinal scale 2. Duration of hospitalization 3. Proportion of participants in each group with need for mechanical ventilation 4. Rate of patients showing improvement of 2 points in 7 category ordinal scale 5. Functional status scale -post covid-19 at 1 week post discharge Follow up visit Timepoint: At Baseline, Day three , Day five and Day seven and at Discharge	—

Measure

Time frame

1. Clinical status as assessed by the 9-point ordinal scale 2. Duration of hospitalization 3. Proportion of participants in each group with need for mechanical ventilation 4. Rate of patients showing improvement of 2 points in 7 category ordinal scale 5. Functional status scale -post covid-19 at 1 week post discharge Follow up visit Timepoint: At Baseline, Day three , Day five and Day seven and at Discharge

—

Countries

India

Contacts

Public ContactDr Vijaykumar Gawali

Bhaktivedanta Hospital and Research Institute

drvijaykumar@bhaktivedantahospital.com9320199122

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026